ID   TIM_HUMAN               Reviewed;        1208 AA.
AC   Q9UNS1; B2ZAV0; O94802; Q86VM1; Q8IWH3;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   28-JUN-2023, entry version 182.
DE   RecName: Full=Protein timeless homolog;
DE            Short=hTIM;
GN   Name=TIMELESS {ECO:0000312|EMBL:AAH50557.1};
GN   Synonyms=TIM {ECO:0000303|PubMed:9856465}, TIM1
GN   {ECO:0000303|PubMed:9891984}, TIMELESS1 {ECO:0000303|PubMed:9891984};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000312|EMBL:BAA36499.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   LEU-455.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA36499.1};
RX   PubMed=9891984; DOI=10.1016/s0014-5793(98)01597-x;
RA   Koike N., Hida A., Numano R., Hirose M., Sakaki Y., Tei H.;
RT   "Identification of the mammalian homologues of the Drosophila timeless
RT   gene, Timeless1.";
RL   FEBS Lett. 441:427-431(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, AND VARIANTS LEU-455 AND GLN-831.
RC   TISSUE=Placenta;
RX   PubMed=9856465; DOI=10.1016/s0896-6273(00)80627-3;
RA   Sangoram A.M., Saez L., Antoch M.P., Gekakis N., Staknis D., Whiteley A.,
RA   Fruechte E.M., Vitaterna M.H., Shimomura K., King D.P., Young M.W.,
RA   Weitz C.J., Takahashi J.S.;
RT   "Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1
RT   interact and negatively regulate CLOCK-ARTNL/BMAL1-induced transcription.";
RL   Neuron 21:1101-1113(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-129; LEU-455; SER-471;
RP   GLN-831; VAL-870; HIS-922; TRP-924; THR-1017 AND LEU-1018.
RG   NIEHS SNPs program;
RL   Submitted (APR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   GLN-831 AND LEU-1018.
RC   TISSUE=Duodenum {ECO:0000312|EMBL:AAH50557.1}, and Skin
RC   {ECO:0000312|EMBL:AAH39842.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, INTERACTION WITH ATR; ATRIP; CHEK1 AND CRY2, AND INDUCTION.
RX   PubMed=15798197; DOI=10.1128/mcb.25.8.3109-3116.2005;
RA   Uensal-Kacmaz K., Mullen T.E., Kaufmann W.K., Sancar A.;
RT   "Coupling of human circadian and cell cycles by the timeless protein.";
RL   Mol. Cell. Biol. 25:3109-3116(2005).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1173, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1173, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   INTERACTION WITH TIPIN.
RX   PubMed=17116885; DOI=10.1073/pnas.0609251103;
RA   Chou D.M., Elledge S.J.;
RT   "Tipin and Timeless form a mutually protective complex required for
RT   genotoxic stress resistance and checkpoint function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18143-18147(2006).
RN   [10]
RP   INTERACTION WITH TIPIN.
RX   PubMed=17102137; DOI=10.1074/jbc.m605596200;
RA   Yoshizawa-Sugata N., Masai H.;
RT   "Human Tim/Timeless-interacting protein, Tipin, is required for efficient
RT   progression of S phase and DNA replication checkpoint.";
RL   J. Biol. Chem. 282:2729-2740(2007).
RN   [11]
RP   SUBCELLULAR LOCATION, INTERACTION WITH CLSPN, AND FUNCTION.
RX   PubMed=17141802; DOI=10.1016/j.jmb.2006.10.097;
RA   Gotter A.L., Suppa C., Emanuel B.S.;
RT   "Mammalian TIMELESS and Tipin are evolutionarily conserved replication
RT   fork-associated factors.";
RL   J. Mol. Biol. 366:36-52(2007).
RN   [12]
RP   INTERACTION WITH TIPIN, AND FUNCTION.
RX   PubMed=17296725; DOI=10.1128/mcb.02190-06;
RA   Uensal-Kacmaz K., Chastain P.D., Qu P.-P., Minoo P., Cordeiro-Stone M.,
RA   Sancar A., Kaufmann W.K.;
RT   "The human Tim/Tipin complex coordinates an Intra-S checkpoint response to
RT   UV that slows replication fork displacement.";
RL   Mol. Cell. Biol. 27:3131-3142(2007).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1149 AND SER-1173, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   REVIEW.
RX   PubMed=20139726; DOI=10.4161/cc.9.4.10676;
RA   McFarlane R.J., Mian S., Dalgaard J.Z.;
RT   "The many facets of the Tim-Tipin protein families' roles in chromosome
RT   biology.";
RL   Cell Cycle 9:700-705(2010).
RN   [17]
RP   INTERACTION WITH DDX11.
RX   PubMed=20124417; DOI=10.1242/jcs.057984;
RA   Leman A.R., Noguchi C., Lee C.Y., Noguchi E.;
RT   "Human Timeless and Tipin stabilize replication forks and facilitate
RT   sister-chromatid cohesion.";
RL   J. Cell Sci. 123:660-670(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1149 AND SER-1173, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   REVIEW.
RX   PubMed=21670590; DOI=10.4161/cc.10.14.15853;
RA   Diaz-Martinez L.A., Clarke D.J.;
RT   "Timeless makes some time for itself.";
RL   Cell Cycle 10:2254-2254(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1149 AND SER-1173, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281; SER-1074; SER-1087;
RP   THR-1089; SER-1149 AND SER-1173, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   FUNCTION.
RX   PubMed=23418588; DOI=10.1371/journal.pone.0056623;
RA   Engelen E., Janssens R.C., Yagita K., Smits V.A., van der Horst G.T.,
RA   Tamanini F.;
RT   "Mammalian TIMELESS is involved in period determination and DNA damage-
RT   dependent phase advancing of the circadian clock.";
RL   PLoS ONE 8:E56623-E56623(2013).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH TIPIN; MCM COMPLEX AND DNA POLYMERASES.
RX   PubMed=23359676; DOI=10.1073/pnas.1222494110;
RA   Cho W.H., Kang Y.H., An Y.Y., Tappin I., Hurwitz J., Lee J.K.;
RT   "Human Tim-Tipin complex affects the biochemical properties of the
RT   replicative DNA helicase and DNA polymerases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:2523-2527(2013).
RN   [25]
RP   INTERACTION WITH DDX11.
RX   PubMed=26503245; DOI=10.1093/nar/gkv1112;
RA   Cali F., Bharti S.K., Di Perna R., Brosh R.M. Jr., Pisani F.M.;
RT   "Tim/Timeless, a member of the replication fork protection complex,
RT   operates with the Warsaw breakage syndrome DNA helicase DDX11 in the same
RT   fork recovery pathway.";
RL   Nucleic Acids Res. 44:705-717(2016).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH PARP1.
RX   PubMed=30356214; DOI=10.1038/s41586-018-0629-6;
RA   Liu H., Zhang H., Wu X., Ma D., Wu J., Wang L., Jiang Y., Fei Y., Zhu C.,
RA   Tan R., Jungblut P., Pei G., Dorhoi A., Yan Q., Zhang F., Zheng R., Liu S.,
RA   Liang H., Liu Z., Yang H., Chen J., Wang P., Tang T., Peng W., Hu Z.,
RA   Xu Z., Huang X., Wang J., Li H., Zhou Y., Liu F., Yan D., Kaufmann S.H.E.,
RA   Chen C., Mao Z., Ge B.;
RT   "Nuclear cGAS suppresses DNA repair and promotes tumorigenesis.";
RL   Nature 563:131-136(2018).
RN   [27]
RP   FUNCTION.
RX   PubMed=35585232; DOI=10.1038/s41586-022-04759-1;
RA   Baris Y., Taylor M.R.G., Aria V., Yeeles J.T.P.;
RT   "Fast and efficient DNA replication with purified human proteins.";
RL   Nature 606:204-210(2022).
RN   [28]
RP   INVOLVEMENT IN FASPS4, VARIANT FASPS4 1081-ARG--ASP-1208 DEL,
RP   CHARACTERIZATION OF VARIANT FASPS4 1081-ARG--ASP-1208 DEL, FUNCTION,
RP   INTERACTION WITH CRY2 AND PER2, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=31138685; DOI=10.1073/pnas.1819110116;
RA   Kurien P., Hsu P.K., Leon J., Wu D., McMahon T., Shi G., Xu Y., Lipzen A.,
RA   Pennacchio L.A., Jones C.R., Fu Y.H., Ptacek L.J.;
RT   "TIMELESS mutation alters phase responsiveness and causes advanced sleep
RT   phase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 116:12045-12053(2019).
RN   [29] {ECO:0007744|PDB:4XHT, ECO:0007744|PDB:4XHU, ECO:0007744|PDB:4XHW}
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1000-1098 IN COMPLEX WITH PARP1,
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PARP1, AND MUTAGENESIS OF
RP   ARG-1081.
RX   PubMed=26344098; DOI=10.1016/j.molcel.2015.07.031;
RA   Xie S., Mortusewicz O., Ma H.T., Herr P., Poon R.Y., Helleday T., Qian C.;
RT   "Timeless interacts with PARP-1 to promote homologous recombination
RT   repair.";
RL   Mol. Cell 60:163-176(2015).
RN   [30] {ECO:0007744|PDB:5MQI}
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1-238 AND 331-463, SUBUNIT, AND
RP   INTERACTION WITH TIPIN.
RX   PubMed=28334766; DOI=10.1093/nar/gkx139;
RA   Holzer S., Degliesposti G., Kilkenny M.L., Maslen S.L., Matak-Vinkovic D.,
RA   Skehel M., Pellegrini L.;
RT   "Crystal structure of the N-terminal domain of human Timeless and its
RT   interaction with Tipin.";
RL   Nucleic Acids Res. 45:5555-5563(2017).
RN   [31] {ECO:0007744|PDB:6T9Q, ECO:0007744|PDB:6TAZ}
RP   X-RAY CRYSTALLOGRAPHY (1.15 ANGSTROMS) OF 883-947, STRUCTURE BY NMR OF
RP   816-954, FUNCTION, AND INTERACTION WITH TIPIN AND DDX11.
RX   PubMed=32705708; DOI=10.15252/embj.2019104185;
RA   Lerner L.K., Holzer S., Kilkenny M.L., Svikovic S., Murat P., Schiavone D.,
RA   Eldridge C.B., Bittleston A., Maman J.D., Branzei D., Stott K.,
RA   Pellegrini L., Sale J.E.;
RT   "Timeless couples G-quadruplex detection with processing by DDX11 helicase
RT   during DNA replication.";
RL   EMBO J. 39:e104185-e104185(2020).
RN   [32] {ECO:0007744|PDB:7PFO}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN REPLISOME, SUBUNIT,
RP   AND FUNCTION.
RX   PubMed=34694004; DOI=10.15252/embj.2021108819;
RA   Jones M.L., Baris Y., Taylor M.R.G., Yeeles J.T.P.;
RT   "Structure of a human replisome shows the organisation and interactions of
RT   a DNA replication machine.";
RL   EMBO J. 40:e108819-e108819(2021).
RN   [33] {ECO:0007744|PDB:7PLO}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) IN REPLISOME, AND
RP   SUBUNIT.
RX   PubMed=34700328; DOI=10.1038/s41586-021-04145-3;
RA   Jenkyn-Bedford M., Jones M.L., Baris Y., Labib K.P.M., Cannone G.,
RA   Yeeles J.T.P., Deegan T.D.;
RT   "A conserved mechanism for regulating replisome disassembly in
RT   eukaryotes.";
RL   Nature 600:743-747(2021).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-429 AND GLU-1008.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Plays an important role in the control of DNA replication,
CC       maintenance of replication fork stability, maintenance of genome
CC       stability throughout normal DNA replication, DNA repair and in the
CC       regulation of the circadian clock (PubMed:9856465, PubMed:17141802,
CC       PubMed:17296725, PubMed:23418588, PubMed:26344098, PubMed:23359676,
CC       PubMed:35585232, PubMed:31138685, PubMed:32705708). Required to
CC       stabilize replication forks during DNA replication by forming a complex
CC       with TIPIN: this complex regulates DNA replication processes under both
CC       normal and stress conditions, stabilizes replication forks and
CC       influences both CHEK1 phosphorylation and the intra-S phase checkpoint
CC       in response to genotoxic stress (PubMed:17141802, PubMed:17296725,
CC       PubMed:23359676, PubMed:35585232). During DNA replication, inhibits the
CC       CMG complex ATPase activity and activates DNA polymerases catalytic
CC       activities, coupling DNA unwinding and DNA synthesis (PubMed:23359676).
CC       TIMELESS promotes TIPIN nuclear localization (PubMed:17141802,
CC       PubMed:17296725). Plays a role in maintaining processive DNA
CC       replication past genomic guanine-rich DNA sequences that form G-
CC       quadruplex (G4) structures, possibly together with DDX1
CC       (PubMed:32705708). Involved in cell survival after DNA damage or
CC       replication stress by promoting DNA repair (PubMed:17141802,
CC       PubMed:17296725, PubMed:26344098, PubMed:30356214). In response to
CC       double-strand breaks (DSBs), accumulates at DNA damage sites and
CC       promotes homologous recombination repair via its interaction with PARP1
CC       (PubMed:26344098, PubMed:30356214, PubMed:31138685). May be
CC       specifically required for the ATR-CHEK1 pathway in the replication
CC       checkpoint induced by hydroxyurea or ultraviolet light
CC       (PubMed:15798197). Involved in the determination of period length and
CC       in the DNA damage-dependent phase advancing of the circadian clock
CC       (PubMed:23418588, PubMed:31138685). Negatively regulates CLOCK|NPAS2-
CC       ARTNL/BMAL1|ARTNL2/BMAL2-induced transactivation of PER1 possibly via
CC       translocation of PER1 into the nucleus (PubMed:9856465,
CC       PubMed:31138685). May play a role as destabilizer of the PER2-CRY2
CC       complex (PubMed:31138685). May also play an important role in
CC       epithelial cell morphogenesis and formation of branching tubules (By
CC       similarity). {ECO:0000250|UniProtKB:Q9R1X4,
CC       ECO:0000269|PubMed:15798197, ECO:0000269|PubMed:17141802,
CC       ECO:0000269|PubMed:17296725, ECO:0000269|PubMed:23359676,
CC       ECO:0000269|PubMed:23418588, ECO:0000269|PubMed:26344098,
CC       ECO:0000269|PubMed:30356214, ECO:0000269|PubMed:31138685,
CC       ECO:0000269|PubMed:32705708, ECO:0000269|PubMed:35585232,
CC       ECO:0000269|PubMed:9856465}.
CC   -!- SUBUNIT: Monomer (PubMed:28334766). Homodimer or homomultimer (By
CC       similarity). Component of the circadian core oscillator, which includes
CC       the CRY proteins, CLOCK or NPAS2, ARTNL/BMAL1 or ARTNL2/BMAL2, CSKN1D
CC       and/or CSNK1E, TIMELESS, and the PER proteins (PubMed:9856465).
CC       Interacts with PER2 (PubMed:31138685). The interaction with PER2 is
CC       direct and via its second PAS domain (By similarity). Interacts
CC       directly with PER1 and PER3 (By similarity). Interacts with CRY2,
CC       CHEK1, ATR and ATRIP (PubMed:15798197, PubMed:31138685). Interacts with
CC       CRY1 (By similarity) (PubMed:15798197). Interacts with CLSPN; the
CC       interaction is required for leading-strand replication
CC       (PubMed:23359676, PubMed:17141802, PubMed:35585232, PubMed:34694004,
CC       PubMed:34700328). Interacts (via N-terminus) with TIPIN
CC       (PubMed:17102137, PubMed:17116885, PubMed:17296725, PubMed:34694004,
CC       PubMed:34700328, PubMed:28334766). The TIMELESS-TIPIN heterodimer binds
CC       preferably to guanine-rich quadruplex-forming (G4) DNA structures
CC       (PubMed:32705708). Associates with the MCM2-7 complex (PubMed:34700328,
CC       PubMed:34694004, PubMed:23359676). Interacts with DNA polymerases
CC       alpha, delta and epsilon (PubMed:23359676). Interacts with DDX11; this
CC       interaction increases recruitment of both proteins onto chromatin in
CC       response to replication stress induction by hydroxyurea
CC       (PubMed:20124417, PubMed:26503245, PubMed:32705708). Interacts with
CC       PARP1; interaction is direct and independent of poly-ADP-ribose
CC       (PubMed:26344098, PubMed:30356214). {ECO:0000250|UniProtKB:Q9R1X4,
CC       ECO:0000269|PubMed:15798197, ECO:0000269|PubMed:17102137,
CC       ECO:0000269|PubMed:17116885, ECO:0000269|PubMed:17141802,
CC       ECO:0000269|PubMed:17296725, ECO:0000269|PubMed:20124417,
CC       ECO:0000269|PubMed:23359676, ECO:0000269|PubMed:26344098,
CC       ECO:0000269|PubMed:26503245, ECO:0000269|PubMed:28334766,
CC       ECO:0000269|PubMed:30356214, ECO:0000269|PubMed:31138685,
CC       ECO:0000269|PubMed:32705708, ECO:0000269|PubMed:34694004,
CC       ECO:0000269|PubMed:34700328, ECO:0000269|PubMed:35585232,
CC       ECO:0000269|PubMed:9856465}.
CC   -!- INTERACTION:
CC       Q9UNS1; O14757: CHEK1; NbExp=2; IntAct=EBI-2212315, EBI-974488;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17141802,
CC       ECO:0000269|PubMed:31138685}. Chromosome {ECO:0000269|PubMed:26344098}.
CC       Note=In response to double-strand breaks (DSBs), accumulates at DNA
CC       damage sites via its interaction with PARP1.
CC       {ECO:0000269|PubMed:26344098}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000269|PubMed:9856465, ECO:0000269|PubMed:9891984};
CC         IsoId=Q9UNS1-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:9856465};
CC         IsoId=Q9UNS1-2; Sequence=VSP_051693;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined including brain,
CC       heart, lung, liver, skeletal muscle, kidney, placenta, pancreas,
CC       spleen, thymus and testis. Highest levels of expression in placenta,
CC       pancreas, thymus and testis. {ECO:0000269|PubMed:9856465,
CC       ECO:0000269|PubMed:9891984}.
CC   -!- INDUCTION: Regulated by the cell cycle. High levels in S, G(2) and M
CC       phases, with highest level in S phase. Low expression in G(0) and G(1)
CC       phases. {ECO:0000269|PubMed:15798197}.
CC   -!- DOMAIN: Residues 1182-1199 comprise a putative nuclear localization
CC       signal; nuclear localization is required for the regulation of period
CC       length of the circadian clock. {ECO:0000269|PubMed:31138685}.
CC   -!- DOMAIN: The DNA-binding domain (residues 816-954) binds to both single-
CC       stranded DNA (ssDNA) and double-stranded DNA (dsDNA), and has high
CC       affinity for DNA sequences rich in guanine that form G-quadruplex (G4)
CC       structures. {ECO:0000269|PubMed:32705708}.
CC   -!- DOMAIN: The C-terminal domain, comprising the DNA-binding domain and
CC       the PARP1-binding region, is required for the replication past genomic
CC       guanine-rich DNA sequences that form G-quadruplex (G4) structures.
CC       {ECO:0000269|PubMed:32705708}.
CC   -!- DISEASE: Advanced sleep phase syndrome, familial, 4 (FASPS4)
CC       [MIM:620015]: An autosomal dominant disorder characterized by very
CC       early sleep onset and offset. Individuals are 'morning larks' with a 4
CC       hours advance of the sleep, temperature and melatonin rhythms.
CC       {ECO:0000269|PubMed:31138685}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the timeless family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH39842.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/timeless/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB015597; BAA36499.1; -; mRNA.
DR   EMBL; AF098162; AAC80011.1; -; mRNA.
DR   EMBL; EU627094; ACD11488.1; -; Genomic_DNA.
DR   EMBL; AC024884; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC039842; AAH39842.1; ALT_SEQ; mRNA.
DR   EMBL; BC050557; AAH50557.1; -; mRNA.
DR   CCDS; CCDS81699.1; -. [Q9UNS1-2]
DR   CCDS; CCDS8918.1; -. [Q9UNS1-1]
DR   RefSeq; NP_001317224.1; NM_001330295.1. [Q9UNS1-2]
DR   RefSeq; NP_003911.2; NM_003920.4. [Q9UNS1-1]
DR   PDB; 4XHT; X-ray; 1.65 A; A/B/C/D=1000-1098.
DR   PDB; 4XHU; X-ray; 2.09 A; B/D=1000-1098.
DR   PDB; 4XHW; X-ray; 2.85 A; A/B/C/D=1000-1098.
DR   PDB; 5MQI; X-ray; 1.85 A; A=1-238, A=331-463.
DR   PDB; 6T9Q; X-ray; 1.15 A; A=883-947.
DR   PDB; 6TAZ; NMR; -; B=816-954.
DR   PDB; 7PFO; EM; 3.20 A; K=1-1208.
DR   PDB; 7PLO; EM; 2.80 A; K=1-1208.
DR   PDBsum; 4XHT; -.
DR   PDBsum; 4XHU; -.
DR   PDBsum; 4XHW; -.
DR   PDBsum; 5MQI; -.
DR   PDBsum; 6T9Q; -.
DR   PDBsum; 6TAZ; -.
DR   PDBsum; 7PFO; -.
DR   PDBsum; 7PLO; -.
DR   AlphaFoldDB; Q9UNS1; -.
DR   SMR; Q9UNS1; -.
DR   BioGRID; 114428; 132.
DR   DIP; DIP-47395N; -.
DR   IntAct; Q9UNS1; 29.
DR   MINT; Q9UNS1; -.
DR   STRING; 9606.ENSP00000450607; -.
DR   iPTMnet; Q9UNS1; -.
DR   PhosphoSitePlus; Q9UNS1; -.
DR   BioMuta; TIMELESS; -.
DR   DMDM; 296452931; -.
DR   EPD; Q9UNS1; -.
DR   jPOST; Q9UNS1; -.
DR   MassIVE; Q9UNS1; -.
DR   MaxQB; Q9UNS1; -.
DR   PaxDb; Q9UNS1; -.
DR   PeptideAtlas; Q9UNS1; -.
DR   ProteomicsDB; 85326; -. [Q9UNS1-1]
DR   ProteomicsDB; 85327; -. [Q9UNS1-2]
DR   Antibodypedia; 15850; 244 antibodies from 31 providers.
DR   DNASU; 8914; -.
DR   Ensembl; ENST00000229201.4; ENSP00000229201.4; ENSG00000111602.12. [Q9UNS1-2]
DR   Ensembl; ENST00000553532.6; ENSP00000450607.1; ENSG00000111602.12. [Q9UNS1-1]
DR   GeneID; 8914; -.
DR   KEGG; hsa:8914; -.
DR   MANE-Select; ENST00000553532.6; ENSP00000450607.1; NM_003920.5; NP_003911.2.
DR   UCSC; uc001slf.3; human. [Q9UNS1-1]
DR   AGR; HGNC:11813; -.
DR   CTD; 8914; -.
DR   DisGeNET; 8914; -.
DR   GeneCards; TIMELESS; -.
DR   HGNC; HGNC:11813; TIMELESS.
DR   HPA; ENSG00000111602; Low tissue specificity.
DR   MalaCards; TIMELESS; -.
DR   MIM; 603887; gene.
DR   MIM; 620015; phenotype.
DR   neXtProt; NX_Q9UNS1; -.
DR   OpenTargets; ENSG00000111602; -.
DR   PharmGKB; PA36520; -.
DR   VEuPathDB; HostDB:ENSG00000111602; -.
DR   eggNOG; KOG1974; Eukaryota.
DR   GeneTree; ENSGT00390000015124; -.
DR   HOGENOM; CLU_003493_0_0_1; -.
DR   InParanoid; Q9UNS1; -.
DR   OMA; KETHDYK; -.
DR   OrthoDB; 2877878at2759; -.
DR   PhylomeDB; Q9UNS1; -.
DR   TreeFam; TF312802; -.
DR   PathwayCommons; Q9UNS1; -.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   SignaLink; Q9UNS1; -.
DR   SIGNOR; Q9UNS1; -.
DR   BioGRID-ORCS; 8914; 760 hits in 1140 CRISPR screens.
DR   ChiTaRS; TIMELESS; human.
DR   GenomeRNAi; 8914; -.
DR   Pharos; Q9UNS1; Tbio.
DR   PRO; PR:Q9UNS1; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q9UNS1; protein.
DR   Bgee; ENSG00000111602; Expressed in ventricular zone and 135 other tissues.
DR   Genevisible; Q9UNS1; HS.
DR   GO; GO:0000785; C:chromatin; IDA:HGNC-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC-UCL.
DR   GO; GO:0031298; C:replication fork protection complex; IBA:GO_Central.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0044770; P:cell cycle phase transition; IMP:BHF-UCL.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:1904976; P:cellular response to bleomycin; IMP:UniProtKB.
DR   GO; GO:0072719; P:cellular response to cisplatin; IMP:UniProtKB.
DR   GO; GO:0072711; P:cellular response to hydroxyurea; IMP:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0009582; P:detection of abiotic stimulus; TAS:ProtInc.
DR   GO; GO:0006974; P:DNA damage response; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0000076; P:DNA replication checkpoint signaling; IBA:GO_Central.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:UniProtKB.
DR   GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0043111; P:replication fork arrest; IBA:GO_Central.
DR   InterPro; IPR044998; Timeless.
DR   InterPro; IPR007725; TIMELESS_C.
DR   InterPro; IPR006906; Timeless_N.
DR   PANTHER; PTHR22940:SF4; PROTEIN TIMELESS HOMOLOG; 1.
DR   PANTHER; PTHR22940; TIMEOUT/TIMELESS-2; 1.
DR   Pfam; PF04821; TIMELESS; 1.
DR   Pfam; PF05029; TIMELESS_C; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms; Cell cycle;
KW   Cell division; Chromosome; Developmental protein; Disease variant;
KW   DNA damage; DNA repair; Mitosis; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation.
FT   CHAIN           1..1208
FT                   /note="Protein timeless homolog"
FT                   /id="PRO_0000072538"
FT   REGION          1..309
FT                   /note="Required for homodimerization and for interaction
FT                   with CRY1 and CHEK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1X4"
FT   REGION          655..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          816..954
FT                   /note="DNA-binding domain"
FT                   /evidence="ECO:0000269|PubMed:32705708"
FT   REGION          971..994
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1000..1098
FT                   /note="Interaction with PARP1"
FT                   /evidence="ECO:0000269|PubMed:26344098"
FT   REGION          1091..1131
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1143..1208
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1182..1199
FT                   /note="Required for nuclear localization"
FT                   /evidence="ECO:0000269|PubMed:31138685"
FT   COMPBIAS        664..679
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        971..991
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1092..1106
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1117..1131
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1145..1173
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1074
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1087
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1089
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1149
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1173
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         177
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9856465"
FT                   /id="VSP_051693"
FT   VARIANT         129
FT                   /note="A -> S (in dbSNP:rs72478986)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_047879"
FT   VARIANT         429
FT                   /note="A -> D (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036435"
FT   VARIANT         455
FT                   /note="I -> L (in dbSNP:rs774027)"
FT                   /evidence="ECO:0000269|PubMed:9856465,
FT                   ECO:0000269|PubMed:9891984, ECO:0000269|Ref.3"
FT                   /id="VAR_021483"
FT   VARIANT         471
FT                   /note="N -> S (in dbSNP:rs72478993)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_047880"
FT   VARIANT         831
FT                   /note="R -> Q (in dbSNP:rs774047)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:9856465, ECO:0000269|Ref.3"
FT                   /id="VAR_021484"
FT   VARIANT         870
FT                   /note="M -> V (in dbSNP:rs61733875)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_047881"
FT   VARIANT         922
FT                   /note="R -> H (in dbSNP:rs72478999)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_047882"
FT   VARIANT         924
FT                   /note="R -> W (in dbSNP:rs72479000)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_047883"
FT   VARIANT         1008
FT                   /note="Q -> E (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs151188513)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036436"
FT   VARIANT         1017
FT                   /note="I -> T (in dbSNP:rs61376834)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_047884"
FT   VARIANT         1018
FT                   /note="P -> L (in dbSNP:rs2291739)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT                   /id="VAR_021485"
FT   VARIANT         1081..1208
FT                   /note="Missing (in FASPS4; reduced protein stability;
FT                   mislocalization in cytoplasm; reduced interaction with
FT                   CRY2; enhanced destabilization of the PER2-CRY2 complex;
FT                   reduced repressor activity of
FT                   CLOCK|NPAS2-ARTNL/BMAL1|ARTNL2/BMAL2-induced
FT                   transactivation of PER1; does not affect interaction with
FT                   PER2; dbSNP:rs1465092391)"
FT                   /evidence="ECO:0000269|PubMed:31138685"
FT                   /id="VAR_087625"
FT   MUTAGEN         1081
FT                   /note="R->G: Abolishes interaction with PARP1."
FT                   /evidence="ECO:0000269|PubMed:26344098"
FT   HELIX           8..15
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   STRAND          17..21
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   STRAND          24..27
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           31..43
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           50..58
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           60..63
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           65..71
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           76..89
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           93..97
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           106..123
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           127..142
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           145..147
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           150..168
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           184..195
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           198..207
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           209..214
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           215..225
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   TURN            226..228
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           231..234
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           336..352
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           354..367
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           369..371
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           376..391
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           396..402
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           405..424
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           426..428
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           429..451
FT                   /evidence="ECO:0007829|PDB:5MQI"
FT   HELIX           824..837
FT                   /evidence="ECO:0007829|PDB:6TAZ"
FT   STRAND          838..843
FT                   /evidence="ECO:0007829|PDB:6TAZ"
FT   HELIX           845..852
FT                   /evidence="ECO:0007829|PDB:6TAZ"
FT   HELIX           860..869
FT                   /evidence="ECO:0007829|PDB:6TAZ"
FT   HELIX           876..880
FT                   /evidence="ECO:0007829|PDB:6TAZ"
FT   HELIX           891..904
FT                   /evidence="ECO:0007829|PDB:6T9Q"
FT   HELIX           910..916
FT                   /evidence="ECO:0007829|PDB:6T9Q"
FT   HELIX           924..933
FT                   /evidence="ECO:0007829|PDB:6T9Q"
FT   STRAND          936..939
FT                   /evidence="ECO:0007829|PDB:6T9Q"
FT   HELIX           940..943
FT                   /evidence="ECO:0007829|PDB:6T9Q"
FT   HELIX           1008..1012
FT                   /evidence="ECO:0007829|PDB:4XHT"
FT   HELIX           1016..1033
FT                   /evidence="ECO:0007829|PDB:4XHT"
FT   STRAND          1042..1044
FT                   /evidence="ECO:0007829|PDB:4XHW"
FT   HELIX           1049..1055
FT                   /evidence="ECO:0007829|PDB:4XHT"
FT   HELIX           1058..1067
FT                   /evidence="ECO:0007829|PDB:4XHT"
FT   TURN            1074..1076
FT                   /evidence="ECO:0007829|PDB:4XHT"
FT   STRAND          1078..1082
FT                   /evidence="ECO:0007829|PDB:4XHW"
FT   HELIX           1088..1096
FT                   /evidence="ECO:0007829|PDB:4XHT"
SQ   SEQUENCE   1208 AA;  138658 MW;  16C6C07DDC6D2701 CRC64;
     MDLHMMNCEL LATCSALGYL EGDTYHKEPD CLESVKDLIR YLRHEDETRD VRQQLGAAQI
     LQSDLLPILT QHHQDKPLFD AVIRLMVNLT QPALLCFGNL PKEPSFRHHF LQVLTYLQAY
     KEAFASEKAF GVLSETLYEL LQLGWEERQE EDNLLIERIL LLVRNILHVP ADLDQEKKID
     DDASAHDQLL WAIHLSGLDD LLLFLASSSA EEQWSLHVLE IVSLMFRDQN PEQLAGVGQG
     RLAQERSADF AELEVLRQRE MAEKKTRALQ RGNRHSRFGG SYIVQGLKSI GERDLIFHKG
     LHNLRNYSSD LGKQPKKVPK RRQAARELSI QRRSALNVRL FLRDFCSEFL ENCYNRLMGS
     VKDHLLREKA QQHDETYYMW ALAFFMAFNR AASFRPGLVS ETLSVRTFHF IEQNLTNYYE
     MMLTDRKEAA SWARRMHLAL KAYQELLATV NEMDISPDEA VRESSRIIKN NIFYVMEYRE
     LFLALFRKFD ERCQPRSFLR DLVETTHLFL KMLERFCRSR GNLVVQNKQK KRRKKKKKVL
     DQAIVSGNVP SSPEEVEAVW PALAEQLQCC AQNSELSMDS VVPFDAASEV PVEEQRAEAM
     VRIQDCLLAG QAPQALTLLR SAREVWPEGD VFGSQDISPE EEIQLLKQIL SAPLPRQQGP
     EERGAEEEEE EEEEEEEELQ VVQVSEKEFN FLDYLKRFAC STVVRAYVLL LRSYQQNSAH
     TNHCIVKMLH RLAHDLKMEA LLFQLSVFCL FNRLLSDPAA GAYKELVTFA KYILGKFFAL
     AAVNQKAFVE LLFWKNTAVV REMTEGYGSL DDRSSSRRAP TWSPEEEAHL RELYLANKDV
     EGQDVVEAIL AHLNTVPRTR KQIIHHLVQM GLADSVKDFQ RKGTHIVLWT GDQELELQRL
     FEEFRDSDDV LGHIMKNITA KRSRARIVDK LLALGLVAER RELYKKRQKK LASSILPNGA
     ESLKDFCQED LEEEENLPEE DSEEEEEGGS EAEQVQGSLV LSNENLGQSL HQEGFSIPLL
     WLQNCLIRAA DDREEDGCSQ AVPLVPLTEE NEEAMENEQF QQLLRKLGVR PPASGQETFW
     RIPAKLSPTQ LRRAAASLSQ PEEEQKLQPE LQPKVPGEQG SDEEHCKEHR AQALRALLLA
     HKKKAGLASP EEEDAVGKEP LKAAPKKRQL LDSDEEQEED EGRNRAPELG APGIQKKKRY
     QIEDDEDD
//
